POZEN Inc. (POZN) Shares Climb 34% on Word of FDA Approval
According to the World Health Organization, more than 303 million people worldwide suffer from migraines. POZEN Inc. is a development stage company focused on such ailments and centered on the development of products for the treatment of acute and chronic pain and pain-related conditions. The company is exploring the development of product candidates in other pain-related therapeutic areas. POZEN Inc. was recently awarded a long-awaited approval from the U.S. Food and Drug Administration for its migraine drug, Treximet. The company first requested approval from the administration in 2005, but was asked twice for more data. Treximet is the only migraine…